Development of MK-4827: A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors

被引：0
|
作者：
Jones, Philip [1 ]
Altamura, Sergio [1 ]
Boueres, Julia [1 ]
Ferrigno, Federica [1 ]
Fonsi, Massimiliano [1 ]
Gavory, Gerald [1 ]
Giomini, Claudia [1 ]
Koch, Uwe [1 ]
Lamartina, Stefania [1 ]
Monteagudo, Edith [1 ]
Ontoria, Jesus M. [1 ]
Roscilli, Giuseppe [1 ]
Rowley, Michael [1 ]
Scarpelli, Rita [1 ]
Schultz-Fademrecht, Carsten [1 ]
Toniatti, Carlo [1 ]
机构：
[1] IRBM Merck Res Labs Rome, I-00040 Pomezia, Italy
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 238卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
220-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of a novel poly (ADP-ribose) polymerase (PARP) inhibitor in rodent models of local inflammation
    Mabley, J
    Virag, L
    Jagtap, P
    Szabo, E
    Prendergast, R
    Perretti, M
    Getting, S
    Szabo, C
    FASEB JOURNAL, 2001, 15 (04): : A242 - A242
  • [22] MK-4827, a novel poly(ADPribose) polymerase (PARP) inhibitor, radiosensitizes non-small cell lung cancer (NSCLC) cells
    Jensen, Kathleen
    Gavory, Gerald
    Toniatti, Carlo
    Meyn, Raymond
    CANCER RESEARCH, 2009, 69
  • [23] Differential contribution of poly(ADP-ribose)polymerase-1 and-2 (PARP-1 and-2) to the poly(ADP-ribosyl)ation reaction in rat primary spermatocytes
    Tramontano, F.
    Malanga, M.
    Quesada, P.
    MOLECULAR HUMAN REPRODUCTION, 2007, 13 (11) : 821 - 828
  • [24] Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1
    Mukul R. Jain
    Jogeswar Mohapatra
    Debdutta Bandhyopadhyay
    Abhijit Chatterjee
    Krishnarup Ghoshdastidar
    Dinesh Patel
    Ankit Patel
    Hitesh Bhayani
    Brijesh Kumar Srivastava
    Sandeep A. Shedage
    Pravin Kadam
    Rajesh Sundar
    Harilal Patel
    Poonam Giri
    Prakash Patel
    Laxmikant Gupta
    Nuggehally R. Srinivas
    Pankaj R. Patel
    Ranjit C. Desai
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 635 - 647
  • [25] Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1
    Jain, Mukul R.
    Mohapatra, Jogeswar
    Bandhyopadhyay, Debdutta
    Chatterjee, Abhijit
    Ghoshdastidar, Krishnarup
    Patel, Dinesh
    Patel, Ankit
    Bhayani, Hitesh
    Srivastava, Brijesh Kumar
    Shedage, Sandeep A.
    Kadam, Pravin
    Sundar, Rajesh
    Patel, Harilal
    Giri, Poonam
    Patel, Prakash
    Gupta, Laxmikant
    Srinivas, Nuggehally R.
    Patel, Pankaj R.
    Desai, Ranjit C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 635 - 647
  • [26] Human biotransformation of olaparib (AZD2281) an oral poly(ADP-ribose) polymerase (PARP) inhibitor
    Clarkson-Jones, J.
    Page, C.
    Sarda, S.
    Swaisland, H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 132 - 132
  • [27] Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report
    Lemech C.R.
    Williams R.
    Thompson S.R.
    McCaughan B.
    Chin M.
    BMC Research Notes, 9 (1)
  • [28] DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1 (PARP1) INHIBITORS FOR THE TREATMENT OF SOLID TUMORS
    Priyancy, J.
    Bhumika, D. P.
    CONFERENCE ON DRUG DESIGN AND DISCOVERY TECHNOLOGIES, 2020, 355 : 31 - 35
  • [29] Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
    Shih, Chi-Ting
    Huang, Tzu-Ting
    Nair, Jayakumar R.
    Ibanez, Kristen R.
    Lee, Jung-Min
    CELLS, 2024, 13 (22)
  • [30] PARP-1 (Poly[ADP-Ribose] Polymerase-1): A Novel Target in Aortic Aneurysm
    Alves-Lopes, Rheure
    Touyz, Rhian M.
    HYPERTENSION, 2018, 72 (05) : 1087 - 1089
12345